These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Chimeric antigen receptor T-cell therapy for ALL. Maude SL; Shpall EJ; Grupp SA Hematology Am Soc Hematol Educ Program; 2014 Dec; 2014(1):559-64. PubMed ID: 25696911 [TBL] [Abstract][Full Text] [Related]
6. CAR T Cell Therapy of Non-hematopoietic Malignancies: Detours on the Road to Clinical Success. Long KB; Young RM; Boesteanu AC; Davis MM; Melenhorst JJ; Lacey SF; DeGaramo DA; Levine BL; Fraietta JA Front Immunol; 2018; 9():2740. PubMed ID: 30559740 [TBL] [Abstract][Full Text] [Related]
8. [Gene-modified T-cell therapy using chimeric antigen receptors for pediatric hematologic malignancies]. Nakazawa Y Rinsho Ketsueki; 2016 Jun; 57(6):701-8. PubMed ID: 27384848 [TBL] [Abstract][Full Text] [Related]
9. From humble beginnings to success in the clinic: Chimeric antigen receptor-modified T-cells and implications for immunotherapy. Firor AE; Jares A; Ma Y Exp Biol Med (Maywood); 2015 Aug; 240(8):1087-98. PubMed ID: 25956686 [TBL] [Abstract][Full Text] [Related]
10. Synergistic and persistent effect of T-cell immunotherapy with anti-CD19 or anti-CD38 chimeric receptor in conjunction with rituximab on B-cell non-Hodgkin lymphoma. Mihara K; Yanagihara K; Takigahira M; Kitanaka A; Imai C; Bhattacharyya J; Kubo T; Takei Y; Yasunaga S; Takihara Y; Kimura A Br J Haematol; 2010 Oct; 151(1):37-46. PubMed ID: 20678160 [TBL] [Abstract][Full Text] [Related]
11. CAR T-cells merge into the fast lane of cancer care. Frey NV; Porter DL Am J Hematol; 2016 Jan; 91(1):146-50. PubMed ID: 26574400 [TBL] [Abstract][Full Text] [Related]
12. A review of CD19-targeted immunotherapies for relapsed or refractory acute lymphoblastic leukemia. DasGupta RK; Marini BL; Rudoni J; Perissinotti AJ J Oncol Pharm Pract; 2018 Sep; 24(6):453-467. PubMed ID: 28583018 [TBL] [Abstract][Full Text] [Related]
13. Insights into cytokine release syndrome and neurotoxicity after CD19-specific CAR-T cell therapy. Gauthier J; Turtle CJ Curr Res Transl Med; 2018 May; 66(2):50-52. PubMed ID: 29625831 [TBL] [Abstract][Full Text] [Related]
14. CAR T-Cell Therapy in Hematologic Malignancies: A Voyage in Progress. Holstein SA; Lunning MA Clin Pharmacol Ther; 2020 Jan; 107(1):112-122. PubMed ID: 31622496 [TBL] [Abstract][Full Text] [Related]
16. Chimeric antigen receptors for the adoptive T cell therapy of hematologic malignancies. Davila ML; Bouhassira DC; Park JH; Curran KJ; Smith EL; Pegram HJ; Brentjens R Int J Hematol; 2014 Apr; 99(4):361-71. PubMed ID: 24311149 [TBL] [Abstract][Full Text] [Related]
17. 4-1BB costimulation ameliorates T cell exhaustion induced by tonic signaling of chimeric antigen receptors. Long AH; Haso WM; Shern JF; Wanhainen KM; Murgai M; Ingaramo M; Smith JP; Walker AJ; Kohler ME; Venkateshwara VR; Kaplan RN; Patterson GH; Fry TJ; Orentas RJ; Mackall CL Nat Med; 2015 Jun; 21(6):581-90. PubMed ID: 25939063 [TBL] [Abstract][Full Text] [Related]
18. Clinical overview of anti-CD19 BiTE(®) and ex vivo data from anti-CD33 BiTE(®) as examples for retargeting T cells in hematologic malignancies. Zugmaier G; Klinger M; Schmidt M; Subklewe M Mol Immunol; 2015 Oct; 67(2 Pt A):58-66. PubMed ID: 25883042 [TBL] [Abstract][Full Text] [Related]
20. Biology and clinical application of CAR T cells for B cell malignancies. Davila ML; Sadelain M Int J Hematol; 2016 Jul; 104(1):6-17. PubMed ID: 27262700 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]